Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)

Saponaro, Miriam; Giacomini, Isabella; Morandin, Giulia; Cocetta, Veronica; Ragazzi, Eugenio; Orso, Genny; Carnevali, Ilaria; Berretta, Massimiliano; Mancini, Mariangela; Pagano, Francesco; Montopoli, Monica

doi:10.3390/ijms21239178

Cited by 20 publications

(17 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study found that the tested extracts, either alone or in combination, were able to reduce ROS production and NF-κB and PGE2 activity in prostate specimens challenged with LPS. The antioxidant and anti-inflammatory activity of a combined formulation of SPE and Urtica dioica in an in vitro human model of BPH was evaluated in another study performed by Saponaro et al The results showed that SPE and U. dioica reduced ROS production, NF-κB translocation inside the nucleus, and interleukin 6(IL-6) and interleukin 8(IL-8) production, confirming both the antioxidant and antiinflammatory effects of SPE and U. dioica 39. Anti-Proliferative and Pro-Apoptotic Effects.…”

mentioning

confidence: 83%

“…47 SPE + Selenium + Lycopene in combination with tamsulosin is more efficacious than single therapies in improving IPSS and increasing maximal urinary flow-rate in patients affected by LUTS/BPH. Other combination therapies, such as with tamsulosin, [48][49][50] Urtica dioica, 39 Pinus pinaster 36 and Peucedanum japonicum, 51 have also shown positive results in co-prescriptions for treating BPH and BPH-linked disorders.…”

Section: Clinical Application Of Spe In Urinary System Diseasesmentioning

confidence: 99%

“…The antioxidant and anti-inflammatory activity of a combined formulation of SPE and Urtica dioica in an in vitro human model of BPH was evaluated in another study performed by Saponaro et al The results showed that SPE and U. dioica reduced ROS production, NF-κB translocation inside the nucleus, and interleukin 6(IL-6) and interleukin 8(IL-8) production, confirming both the antioxidant and anti-inflammatory effects of SPE and U. dioica . 39…”

Section: Pharmacological Effects Of Spementioning

confidence: 99%

See 2 more Smart Citations

The Therapeutic Potential of Saw Palmetto Extract in Urological Disorders

Yin

Wang

et al. 2021

Natural Product Communications

View full text Add to dashboard Cite

Saw palmetto extract (SPE) has been widely used as a therapeutic remedy for urinary dysfunction in western countries. Furthermore, as an herb drug, it can be used as an alternative therapy for benign prostatic hyperplasia (BPH) due to its safety and minimum adverse effects. Reportedly, SPE improves the urinary symptoms, which mainly depend on anti-androgenic effects and effects on autonomic receptors in the lower urinary tract. However, the mechanisms of action responsible for the therapeutic roles of SPE have not been fully elucidated. Relevant studies indicate that SPE has some positive effects on the treatment of urological diseases in animals, and clinical trials are ongoing. In this review, we summarize the pharmacological properties and discuss the possible therapeutic mechanisms of SPE in urological diseases, including anti-androgenic effects, effects on autonomic receptors in the lower urinary tract, anti-inflammatory activity, anti-proliferative and pro-apoptotic effects, and highlight a potential therapeutic approach in the clinical treatment of patients with BPH, prostate cancer, chronic prostatitis (CP) and erectile dysfunction (ED).

show abstract

mentioning

confidence: 83%

Section: Clinical Application Of Spe In Urinary System Diseasesmentioning

confidence: 99%

Section: Pharmacological Effects Of Spementioning

confidence: 99%

See 1 more Smart Citation

The Therapeutic Potential of Saw Palmetto Extract in Urological Disorders

Yin

Wang

et al. 2021

Natural Product Communications

View full text Add to dashboard Cite

show abstract

“…HaCaT cells (5 × 10 3 ) were seeded into 96-well plates, allowed to adhere overnight, and then treated for 24 hours with the compounds, according to the experimental protocol. ROS levels were measured after the addition of 100 μM DCF-DA, further incubation for 30 min at 37 °C, and wash with phosphate-buffered saline (PBS) [17] as previously described. N-acetyl-L-cysteine 5 mM (Sigma Aldrich) and Rutin at 0.1% w/v were used as positive controls and the Melissa officinalis phytocomplex was used at 0.1% w/v.…”

Section: Evaluation Of Ros Levels In Immortalized Keratinocyte Cell Lmentioning

confidence: 99%

In Vitro Cultured Melissa officinalis Cells as Effective Ingredient to Protect Skin against Oxidative Stress, Blue Light, and Infrared Irradiations Damages

et al. 2021

Self Cite

View full text Add to dashboard Cite

Skin is being increasingly exposed to artificial blue light due to the extensive use of electronic devices, which can induce cell oxidative stress, causing signs of early photo aging. The Melissa officinalis phytocomplex is a new standardized cosmetic ingredient obtained by an in vitro plant cell culture with a high content of rosmarinic acid. In this study, we examine the activity of the Melissa officinalis phytocomplex to protect skin against blue light and infrared damages, evaluating the ROS (Radical Oxygen Species) level in keratinocyte cell line from human skin (HaCaT) and Nrf2 (Nuclear factor erythroid 2-related factor 2), elastin, and MMP1 (Matrix Metalloproteinase 1) immunostaining in living human skin explants ex vivo. This phytocomplex demonstrates antioxidant activity by reducing ROS production and thus the oxidant damage of the skin caused by UV and blue light exposure. In addition, it inhibits blue light-induced Nrf2 transcriptional activity, IR-induced elastin alteration, and IR-induced MMP-1 release. This Melissa officinalis phytocomplex is a new innovative active ingredient for cosmetic products that is able to protect skin against light and screen exposure damages and oxidative stress.

show abstract

“…Можливість антипроліферативної дії екстракту кропиви у випадках доброякісних захворювань ПЗ є визнаним науковим фактом [27,28]. Дослідженнями було встановлено можливість впливу екстракту кропиви на зменшення вираженості запальної реакції у вогнищах хронічного запалення та гіперплазії ПЗ із покращенням біохімічних констант у субстратах сім'яних пухирців та стану сечовипускання [29][30][31].…”

Section: анализ эффективности различных видов консервативной терапии ...unclassified

Analysis of the Effectiveness of Various Types of Conservative Therapy for Chronic Bacterial Prostatitis

Gorpynchenko¹,

Gurzhenko²,

Spyrydonenko³

2021

View full text Add to dashboard Cite

The management of patients with chronic bacterial prostatitis (CBP) is associated with a number of challenges. In particular, even in case of pathogen identification, targeted antimicrobial therapy does not reliably control the activity of the inflammatory process and pain syndrome. In addition to the pain syndrome, the clinical picture is aggravated by disorders of urination, sexual function and psycho-emotional sphere, which requires the inclusion of appropriate means of correction in the treatment program. In addition, as result of the chronic course of the disease, repeated and long courses of treatment should be carried out, putting forward additional requirements for the safety of the drugs used. Thus, the development of effective and safe protocols for the management of patients with CBP is an actual scientific task. Given the wide range of biological effects, plant and animal extracts have the potential to enhance the effectiveness of standard CBP treatment. The objective: to compare the efficacy and safety of adding to the standard therapy (ST) CBP, regulated by the protocol of medical care of the Ministry of Health of Ukraine, biologically active plant substances (dwarf palm, stinging nettle, ginkgo biloba, Japanese bitterness, lovage, calendula officinalis) and animal (peptides isolated from the prostate of sexually mature gobies) origin in the form of capsules and suppositories. Materials and methods. The study included 105 patients with CBP, aged from 26 to 39 years and duration of the disease from 6 months to 5 years. Depending on the treatment program, patients were randomized into three groups of equal size (n=35): group I – ST + 1 capsule and 1 rectal suppository per day with plant extracts (PE), group II – ST + 1 rectal suppository with PE per day, ІІІ group – ST + 1 rectal suppository with animal extract (AE). Composition of 1 capsule with PE: dwarf palm berry extract – 160 mg; stinging nettle extract – 100 mg; ginkgo biloba extract – 20 mg; Japanese knotweed extract – 20 mg; selenium methionine – 15 mg. Composition of 1 suppository with PE: extract of dwarf palm berries – 150 mg, extract of lovage roots – 50 mg, extract of calendula flowers – 50 mg. Composition of 1 suppository with AE: prostate extract of sexually mature bulls – 30 mg. The therapy lasted 30 days. At the end of therapy, the groups were compared with each other in terms of changes in pain syndrome (NIH CPSI), results of digital rectal examination, intensiveness of lower urinary tract symptoms (IPSS/QoL), sexual function (IIEF), activity of the inflammatory reaction of metabolism in the prostate (leukocyte count, lecithin grains in the field of view during light microscopy of prostatic secretion), the size of the prostate, the frequency of detection of sonographic artifacts (ultrasound examination), the maximum flow rate – Qmax, urination time – Tu (uroflowmetry), the frequency and nature of undesirable phenomena. To assess the significance of differences, the Student and Fisher tests were used. Significance level – 0.05. Results. Initially, the following disorders were recorded in groups I, II and III: pain syndrome – in 45.7%, 37.1% and 40% of patients, respectively, dysuria – in 62.9%, 51.4% and 54.3%, premature ejaculation (PEj) – in 31.9%, 34.3%, 40%, erectile dysfunction (ED) – in 20%, 14.3%, 20%, calcifications in the prostate – in 45.7%, 40%, 34.3%, diffuse changes in the pancreas. The most common pathogen in all groups was Escherichia coli: it was identified in 42.9%, 54.3% and 60% of patients, respectively. The second and third places in the frequency of detection were taken by Streptococcus faecalis (38.1%) and Staphylococcus aureus (16.2%). At the end of therapy, a decrease in the intensity of pain sensations was recorded in all groups, but the most pronounced – in group I. Thus, in group I, the rate of decrease in the indicator was 15.8 times, in contrast to 4.3 times in group II, and 2.9 times in group III (p<0.001). Pain on palpation of the pancreas was arrested in 100% of patients in group I, in 91.4% in group II, in 88.6% in group III (p<0.001). The decrease in the intensity of dysuria was also more significant in group I. The addition of a combination of PE in the form of capsules and suppositories to ST was associated with a more pronounced decrease in the proportion of patients with PEj and ED. In group I, their share decreased by 3.7 and 3.5 times, respectively, while in group II – by 2 and 2.5 times, and in group III – by 2 and 2.3 times (p<0.001). All three modes of therapy effectively reduced the activity of the inflammatory reaction (a decrease in the number of leukocytes in the pancreas secretion in the field of view), but did not differ in the severity of this effect (p>0.05). Only in group I statistically significant changes in the frequency of daytime and nighttime urination were recorded, which decreased by 21% and 50%, respectively. Although IPSS and QoL improved in all groups, the groups, where PE were used, did not differ in the magnitude of changes in these parameters (p>0.05). The frequency of detecting diffuse and focal changes in the echostructure of the prostate also decreased in all three groups. All three treatment regimens significantly increased Qmax (on average by 1.7 times) and reduced Tu (on average by 1.66 times), but these effects did not differ statistically significantly. Also, there were no significant intergroup differences in the change in the integral indicator of the NIH CPSI scale and the effectiveness of pathogen eradication. In particular, in group I it decreased from 39.3±2.2 to 18.3±1.8 points (p<0.01); in group II – from 37.4±2.7 to 21.3±0.19 points (p<0.01); in group III – from 37.9±2.4 to 22.3±1.9 points (p<0.01). Eradication of the pathogen was achieved in 97.1%, 91.4% and 85.7%, respectively. All three therapeutic regimens were characterized by a satisfactory safety profile: adverse events in the form of a transient skin rash occurred in 1 (2.9%) patient from group I, in 2 (5.7%) patients from group II, and in 2 (5, 7%) of patients from group III. When comparing the groups in accordance with the integral assessment of treatment results, it was found that the proportion of patients assessing the effect as “high” was significantly higher in group I – 57.1% in contrast to 48.6% and 37.1% in II and III groups, respectively. Conclusion. The multisyndromic nature of CBP makes it possible to include in the therapy program extracts of plant and animal origin, which have a wide range of biological effects. Adding of the PE in the form of capsules and rectal suppositories to standard treatment of CBP is scientifically approved, since it is statistically significantly more effective. than PE in the form of capsules and AE in the form of suppositories in correction of pain syndrome, sexual disorders, dysuria, day and night pollakiuria, and is characterized by a higher integral assessment of the effect. The effect of ST with the inclusion of PE in the form of capsules and rectal suppositories on the activity of inflammation, urination parameters, and pathogen eradication can be compared with that of ST + PE in the form of capsules and ST + AE in the form of suppositories. The addition of the plant and animal extracts to ST is safe. Long-term studies are required to evaluate the possibility of ST + PE in the form of capsules and rectal suppositories to influence the size of the prostate.

show abstract

Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)

Cited by 20 publications

References 52 publications

The Therapeutic Potential of Saw Palmetto Extract in Urological Disorders

The Therapeutic Potential of Saw Palmetto Extract in Urological Disorders

In Vitro Cultured Melissa officinalis Cells as Effective Ingredient to Protect Skin against Oxidative Stress, Blue Light, and Infrared Irradiations Damages

Analysis of the Effectiveness of Various Types of Conservative Therapy for Chronic Bacterial Prostatitis

Contact Info

Product

Resources

About